/PRNewswire/ DelveInsight s Multiple Myeloma Market Insights report includes a comprehensive understanding of current treatment practices, multiple myeloma.
Share this article
Share this article
ResearchAndMarkets.com s offering.
Multiple myeloma is characterized by the infiltration of malignant, antibody-producing plasma cells in the bone marrow. Almost all cases occur in individuals aged over 40 years, and age at diagnosis has an impact on patient outcome, especially in terms of the treatment options available. Most patients will receive at least three lines of treatment, and eligible patients will receive stem cell transplantation.
Latest Key Takeaways
The report estimates that in 2018, there were 134,100 incident cases of multiple myeloma (MM) in adults aged 40 years and older worldwide, and expects that number to increase to 153,700 incident cases by 2027.